Elosulfase alfa
| Clinical data | |
|---|---|
| Trade names | Vimizim |
| AHFS/Drugs.com | Multum Consumer Information |
| |
| |
| Identifiers | |
| 9025-60-9 | |
| A16AB12 | |
| Chemical data | |
| Formula | C5020H7588N1364O1418S34 |
| 110.8 kDa | |
Elosulfase alfa (trade name Vimizim) is a drug for the treatment of Morquio syndrome which is caused by a deficiency in the enzyme N-acetylgalactosamine-6-sulfatase. Elosulfase alfa is a synthetic version of this enzyme.
Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and approved for use in the US by the Food and Drug Administration in 2014.[1]